L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism
Abstract 18F-FDG PET/CT has been used as an indicator of chemotherapy effects, but cancer cells can remain even when no FDG uptake is detected, indicating the importance of exploring other metabolomic pathways. Therefore, we explored the amino acid metabolism, including L-type amino acid transporter...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d8250aa6fd4543e7bd61b2f89b38002b |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:d8250aa6fd4543e7bd61b2f89b38002b |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:d8250aa6fd4543e7bd61b2f89b38002b2021-12-02T14:12:45ZL-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism10.1038/s41598-020-80668-52045-2322https://doaj.org/article/d8250aa6fd4543e7bd61b2f89b38002b2021-01-01T00:00:00Zhttps://doi.org/10.1038/s41598-020-80668-5https://doaj.org/toc/2045-2322Abstract 18F-FDG PET/CT has been used as an indicator of chemotherapy effects, but cancer cells can remain even when no FDG uptake is detected, indicating the importance of exploring other metabolomic pathways. Therefore, we explored the amino acid metabolism, including L-type amino acid transporter-1 (LAT1), in breast cancer tissues and clarified the role of LAT1 in therapeutic resistance and clinical outcomes of patients. We evaluated LAT1 expression before and after neoadjuvant chemotherapy and examined the correlation of glucose uptake using FDG-PET with the pathological response of patients. It revealed that LAT1 levels correlated with proliferation after chemotherapy, and amino acid and glucose metabolism were closely correlated. In addition, LAT1 was considered to be involved in treatment resistance and sensitivity only in luminal type breast cancer. Results of in vitro analyses revealed that LAT1 promoted amino acid uptake, which contributed to energy production by supplying amino acids to the TCA cycle. However, in MCF-7 cells treated with chemotherapeutic agents, oncometabolites and branched-chain amino acids also played a pivotal role in energy production and drug resistance, despite decreased glucose metabolism. In conclusion, LAT1 was involved in drug resistance and could be a novel therapeutic target against chemotherapy resistance in luminal type breast cancer.Miku SatoNarumi Harada-ShojiTakafumi ToyoharaTomoyoshi SogaMasatoshi ItohMinoru MiyashitaHiroshi TadaMasakazu AmariNaohiko AnzaiShozo FurumotoTakaaki AbeTakashi SuzukiTakanori IshidaHironobu SasanoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Miku Sato Narumi Harada-Shoji Takafumi Toyohara Tomoyoshi Soga Masatoshi Itoh Minoru Miyashita Hiroshi Tada Masakazu Amari Naohiko Anzai Shozo Furumoto Takaaki Abe Takashi Suzuki Takanori Ishida Hironobu Sasano L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism |
| description |
Abstract 18F-FDG PET/CT has been used as an indicator of chemotherapy effects, but cancer cells can remain even when no FDG uptake is detected, indicating the importance of exploring other metabolomic pathways. Therefore, we explored the amino acid metabolism, including L-type amino acid transporter-1 (LAT1), in breast cancer tissues and clarified the role of LAT1 in therapeutic resistance and clinical outcomes of patients. We evaluated LAT1 expression before and after neoadjuvant chemotherapy and examined the correlation of glucose uptake using FDG-PET with the pathological response of patients. It revealed that LAT1 levels correlated with proliferation after chemotherapy, and amino acid and glucose metabolism were closely correlated. In addition, LAT1 was considered to be involved in treatment resistance and sensitivity only in luminal type breast cancer. Results of in vitro analyses revealed that LAT1 promoted amino acid uptake, which contributed to energy production by supplying amino acids to the TCA cycle. However, in MCF-7 cells treated with chemotherapeutic agents, oncometabolites and branched-chain amino acids also played a pivotal role in energy production and drug resistance, despite decreased glucose metabolism. In conclusion, LAT1 was involved in drug resistance and could be a novel therapeutic target against chemotherapy resistance in luminal type breast cancer. |
| format |
article |
| author |
Miku Sato Narumi Harada-Shoji Takafumi Toyohara Tomoyoshi Soga Masatoshi Itoh Minoru Miyashita Hiroshi Tada Masakazu Amari Naohiko Anzai Shozo Furumoto Takaaki Abe Takashi Suzuki Takanori Ishida Hironobu Sasano |
| author_facet |
Miku Sato Narumi Harada-Shoji Takafumi Toyohara Tomoyoshi Soga Masatoshi Itoh Minoru Miyashita Hiroshi Tada Masakazu Amari Naohiko Anzai Shozo Furumoto Takaaki Abe Takashi Suzuki Takanori Ishida Hironobu Sasano |
| author_sort |
Miku Sato |
| title |
L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism |
| title_short |
L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism |
| title_full |
L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism |
| title_fullStr |
L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism |
| title_full_unstemmed |
L-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism |
| title_sort |
l-type amino acid transporter 1 is associated with chemoresistance in breast cancer via the promotion of amino acid metabolism |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/d8250aa6fd4543e7bd61b2f89b38002b |
| work_keys_str_mv |
AT mikusato ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT narumiharadashoji ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT takafumitoyohara ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT tomoyoshisoga ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT masatoshiitoh ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT minorumiyashita ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT hiroshitada ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT masakazuamari ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT naohikoanzai ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT shozofurumoto ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT takaakiabe ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT takashisuzuki ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT takanoriishida ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism AT hironobusasano ltypeaminoacidtransporter1isassociatedwithchemoresistanceinbreastcancerviathepromotionofaminoacidmetabolism |
| _version_ |
1718391815310147584 |